Overview

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of bevacizumab (Avastin) and temsirolimus (Torisel) that can be given with 1 of 3 other study drugs --carboplatin (Paraplatin), paclitaxel (Taxol), or sorafenib (Nexavar). The safety of these drug combinations will also be studied.

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Everolimus
Niacinamide
Paclitaxel
Sirolimus
Sorafenib